Merck Sharp & Dohme B.v., Merck Sharp & Dohme, LLC v. Aurobindo Pharma USA, Inc., Aurobindo Pharma Ltd., Usv Private Limited, Gland Pharma…

United States Court of Appeals
for the Federal Circuit
______________________
March 19, 2025
ERRATUM
______________________
Appeal No. 2023-2254
MERCK SHARP & DOHME B.V., MERCK SHARP &
DOHME, LLC,
Plaintiffs-Appellees
v.
AUROBINDO PHARMA USA, INC., AUROBINDO
PHARMA LTD., USV PRIVATE LIMITED, GLAND
PHARMA LIMITED, MANKIND PHARMA LTD.,
LIFESTAR PHARMA LLC, FRESENIUS KABI USA,
LLC, DR. REDDY'S LABORATORIES, INC., DR.
REDDY'S LABORATORIES, LTD., SUN
PHARMACEUTICAL INDUSTRIES, INC., SUN
PHARMACEUTICAL INDUSTRIES LIMITED,
SANDOZ INC., LEK PHARMACEUTICALS, D.D.,
MYLAN API US LLC, MYLAN PHARMACEUTICALS
INC., MYLAN INC., EUGIA PHARMA SPECIALTIES
LIMITED,
Defendants-Appellants
LUPIN LTD., LUPIN PHARMACEUTICALS, INC.,
LUPIN INC., TEVA PHARMACEUTICALS USA,
INC.,
Defendants
Case: 23-2254 Document: 120 Page: 1 Filed: 03/19/2025

-- 1 of 2 --

2
______________________
Decided: March 13, 2025
Precedential Opinion
______________________
Please make the following change:
The word “originally” should be changed to “origi-
nal” in the third line of the last paragraph on page 15 so
that the sentence reads:
Merck’s reliance on language that provides
that reissued claims that are “substantially iden-
tical” to the claims in an original patent “shall . . .
have effect continuously from the date of the orig-
inal patent” is similarly misplaced.
Case: 23-2254 Document: 120 Page: 2 Filed: 03/19/2025

-- 2 of 2 --